Sandig Volker  

Biography

  Dr. Volker Sandig, PhD has been Chief Scientific Officer of ProBioGen AG since April 2010. Dr. Sandig served as Vice President of Cell & Vector Biology at ProBioGen AG. Dr. Sandig was responsible for ProBioGen's cell line development programme which he initiated in 2000. As Project Leader, he attracted and directed the Research and Development programme for Merck and Co Inc., which resulted in the creation of a new cell line with predefined features for Merck. In his former position at the Merck Research Laboratories, USA , Dr. Sandig was instrumental in the development of manufacturing systems for gutless adenoviruses. Using his knowledge in viral vectors, he also participated in Merck´s HIV vaccine programme. Earlier in his career, he designed experimental strategies for adenovirus-based tumour treatment and directed research projects in cell cycle regulation and artificial promoters at the Max Planck Society and Hepavec, a former Berlin-based biotech company. After finishing medical training, Dr. Sandig received his PhD in Molecular Biology from the Humboldt University, Berlin.  

Research Interest

 tumor treatment